Literature DB >> 12209735

Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway.

Hao Zhang1, Iwata Ozaki, Toshihiko Mizuta, Sachiko Matsuhashi, Tohru Yoshimura, Akitaka Hisatomi, Jutaro Tadano, Takahiro Sakai, Kyosuke Yamamoto.   

Abstract

BACKGROUND: beta 1-integrin modulates cellular phenotype by mediating signals from the extracellular matrix (ECM). Although overexpression of integrin molecules in hepatocellular carcinoma (HCC) has been reported, the role of overexpressed beta 1-integrin in the disease process of HCC is not fully understood. The authors investigated the effects of beta 1-integrin on apoptosis in hepatoma cells.
METHODS: Human hepatoma cell lines HepG2, Huh7, and HLE were stably transfected with full-length beta 1-integrin. Cells underwent apoptosis induced by chemotherapeutic reagents, including cis-platinum (II)-diammine dichloride, etoposide, and docetaxel. Cell survival and intracellular signaling pathways dependent on beta 1-integrin-mediated apoptosis effects were analyzed by treating cells with PD98059 (ERK inhibitor), SB203580 (p38MAP kinase inhibitor), wortmannin (phosphatidyl inositol-3-kinase inhibitor), and herbimycin A (tyrosine kinase inhibitor).
RESULTS: All three hepatoma cell lines overexpressing beta 1-integrin were protected from apoptosis induced by chemotherapeutic reagents, whereas parental or mock transfected cells were not. Treatment with PD98059 or SB203580 abolished the protective effect on apoptosis in cells overexpressing beta 1-integrin. Neither herbimycin nor wortmannin blocked the protective effects of beta 1-integrin overexpression.
CONCLUSIONS: These data suggest that overexpression of beta 1-integrin confers resistance to apoptosis in hepatoma cells via a MAP kinase dependent pathway. beta1-integrin mediated signaling from the ECM in HCC cells may contribute to chemotherapy resistance. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10751

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209735     DOI: 10.1002/cncr.10751

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Fibrosis-dependent mechanisms of hepatocarcinogenesis.

Authors:  David Y Zhang; Scott L Friedman
Journal:  Hepatology       Date:  2012-06-29       Impact factor: 17.425

2.  Comparative proteome analysis of untreated and Helicobacter pylori-treated HepG2.

Authors:  Yan Zhang; Xue-Gong Fan; Ren Chen; Zhi-Qiang Xiao; Xue-Ping Feng; Xue-Fei Tian; Zhao-Hui Chen
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

Review 3.  Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

Authors:  Youngmin A Lee; Scott L Friedman
Journal:  Antiviral Res       Date:  2014-04-12       Impact factor: 5.970

Review 4.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

5.  Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Authors:  Dario Caccia; Francesca Miccichè; Giuliana Cassinelli; Piera Mondellini; Patrizia Casalini; Italia Bongarzone
Journal:  Mol Cancer       Date:  2010-10-18       Impact factor: 27.401

6.  Regulation of TGF-β1-Induced Pro-Apoptotic Signaling by Growth Factor Receptors and Extracellular Matrix Receptor Integrins in the Liver.

Authors:  Iwata Ozaki; Hiroshi Hamajima; Sachiko Matsuhashi; Toshihiko Mizuta
Journal:  Front Physiol       Date:  2011-10-24       Impact factor: 4.566

7.  Bioinformatics approaches for cross-species liver cancer analysis based on microarray gene expression profiling.

Authors:  H Fang; W Tong; R Perkins; L Shi; H Hong; X Cao; Q Xie; S H Yim; J M Ward; H C Pitot; Y P Dragan
Journal:  BMC Bioinformatics       Date:  2005-07-15       Impact factor: 3.169

8.  Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Authors:  E G Seviour; V Sehgal; Y Lu; Z Luo; T Moss; F Zhang; S M Hill; W Liu; S N Maiti; L Cooper; R Azencot; G Lopez-Berestein; C Rodriguez-Aguayo; R Roopaimoole; C V Pecot; C Pecot; A K Sood; S Mukherjee; J W Gray; G B Mills; P T Ram
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

9.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Authors:  Bishoy M Faltas; Davide Prandi; Scott T Tagawa; Ana M Molina; David M Nanus; Cora Sternberg; Jonathan Rosenberg; Juan Miguel Mosquera; Brian Robinson; Olivier Elemento; Andrea Sboner; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Genet       Date:  2016-10-17       Impact factor: 38.330

10.  Advanced cell culture techniques for cancer drug discovery.

Authors:  Carrie J Lovitt; Todd B Shelper; Vicky M Avery
Journal:  Biology (Basel)       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.